SGYP - Synergy Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
-0.0046 (-7.29%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.0631
Bid0.0584 x 800
Ask0.0586 x 1300
Day's Range0.0552 - 0.0640
52 Week Range0.0552 - 0.0640
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit

    See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

    Synergy Pharmaceuticals Inc NASDAQ/NGS:SGYPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SGYP with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding SGYP totaled $4 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Chester County to lose 137 pharma jobs
    American City Business Journals

    Chester County to lose 137 pharma jobs

    A New York biopharmaceutical company is closing its Chesterbrook office after reaching a deal to sell most of its assets.

  • Benzinga

    The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 26) AstraZeneca plc (NYSE: AZN )(announced positive results ...

  • Bausch Health Companies Inc (BHC) Q4 2018 Earnings Conference Call Transcript
    Motley Fool

    Bausch Health Companies Inc (BHC) Q4 2018 Earnings Conference Call Transcript

    BHC earnings call for the period ending December 31, 2018.

  • Zacks

    Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

    Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

  • InvestorPlace

    Synergy Pharmaceuticals Bankruptcy: SGYP Stock Plummets on Filing

    Synergy Pharmaceuticals (NASDAQ:SGYP) has filed for Chapter 11 bankruptcy in a voluntary petition with another pharmaceutical company absorbing most of the company’s assets once the move goes through. The bankruptcy filing will be followed by Bausch Health (NYSE:BHC) taking over as a “stalking horse” bidder for the company in an auction and sale process that has been approved by a court. The acquisition of Synergy’s assets will be part of a deal valued at roughly $200 million that is slated to be complete at the end of the first quarter of 2019.

  • No Emoji Could Hide This Drugmaker’s Woes

    No Emoji Could Hide This Drugmaker’s Woes

    The problem doesn’t appear to have been the stigma around talking about bowel movements — an issue Synergy hoped to address with those (animated!) emojis — but rather a highly competitive market.(2)Trulance has made little headway against better established drugs like Allergan PLC’s Linzess and Takeda Pharmaceutical Co.’s Amitiza.